Syngeneic

While GEMMS off whole animal microenvironment for tumor studies, the PRU has the capability to ramp up project speeds by using syngeneic tumor grafts or cell line implants. Large cohorts of animals can be studied simultaneously to meet the requirements of the project. The current models we have readily available are:

• T11 (Breast) – The T11 model is a transplantable orthotopic model derived from a mammary epithelial tumor containing Trp53  (Jerry et al., Oncogene 2000 – PMID:  10713689).  This model was genomically characterized by Dr. Charles Perou and represents the claudin-low subtype of human breast tumors tumors (Pfefferle et al. Genome Biology 2013 – PMID:  24220145). As subset of the Triple-negative phenotype (ER-, PR-, HER2-), these tumors are seen in 15% of all human breast cases. They are highly refractory to chemotherapy and offer a much worse prognosis for the patient.

• Braf PTEN Tyr-Cre (Melanoma)

• K14pBRCA1_B (Breast)

• BBN (Bladder)

• UPPL (Bladder)

• TRIA (Melanoma)

If you wish to discuss how to incorporate your models in efficacy studies, please contact Dr. Aadra Bhatt at aadra_bhatt@med.unc.edu